Skip to main content
. 2019 Jun 19;6(3):130–141. doi: 10.36469/001c.9682

Table 2. Procedures and Treatments Among Infants diagnosed with HRF/PPHN.

Procedures Total Infants with HRF/PPHN (n=918) Infants with HRF/PPHN
Preterm infants (n=504) T/NT infants (n=414) P-value
Ventilation use, n (%)
Overall 865 (94.2) 474 (94.1) 391 (94.4) 0.7976
Time on ventilation (days), mean (SD) 3.6 (7.7) 4.7 (10.0) 2.2 (2.5) <0.0001
Non-invasive ventilation 334 (36.4) 188 (37.3) 146 (35.3) 0.5235
Invasive mechanical ventilation 836 (91.1) 461 (91.5) 375 (90.6) 0.6386
ECMO, n (%) 46 (5.0) 10 (2.0) 36 (8.7) <0.0001
Treatments, n (%)
Antibiotics 880 (95.9) 485 (96.2) 395 (95.4) 0.5351
Surfactants 544 (59.3) 359 (71.2) 185 (44.7) <0.0001
Sildenafil 82 (8.9) 48 (9.5) 34 (8.2) 0.4882
Inhaled nitric oxide 863 (94.0) 473 (93.8) 390 (94.2) 0.8222
Time on inhaled nitric oxide (days), mean (SD) 7.2 (11.2) 8.2 (12.5) 5.9 (9.1) 0.0017
Mortality rate, n (%) 240 (26.1) 152 (30.2) 88 (21.3) 0.0023

ECMO: Extracorporeal membrane oxygenation; HRF: hypoxic respiratory failure; PPHN: persistent pulmonary hypertension of newborn; SD: standard deviation; T/NT: term/near term